MedTrace Logo

Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy

NCT01153672 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2019-09-06

Study results available
· View outcomes & findings →

Summary

This pilot clinical trial studies vorinostat in treating patients with stage IV breast cancer receiving aromatase inhibitor (AI) therapy. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vorinostat may also help AI therapy work better by making tumor cells more sensitive to the drug

Conditions

  • Male Breast Cancer
  • Recurrent Breast Cancer
  • Stage IV Breast Cancer

Interventions

DRUG

vorinostat

Given PO

OTHER

laboratory biomarker analysis

Correlative studies

PROCEDURE

biopsy

Optional correlative studies

RADIATION

F-18 16 alpha-fluoroestradiol

Correlative studies

PROCEDURE

positron emission tomography

Correlative studies

DRUG

anastrozole

Given PO

DRUG

letrozole

Given PO

DRUG

exemestane

Given PO

GENETIC

gene expression analysis

Correlative studies

Sponsors & Collaborators

Principal Investigators

  • Hannah Linden · Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2012-07-31
Completion
2016-08-11

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01153672 on ClinicalTrials.gov